A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Tumors or cancer of the ADRENAL GLANDS.
A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
A relatively rare, usually benign neoplasm originating in the chemoreceptor tissue of the CAROTID BODY; GLOMUS JUGULARE; GLOMUS TYMPANICUM; AORTIC BODIES; and the female genital tract. It consists histologically of rounded or ovoid hyperchromatic cells that tend to be grouped in an alveolus-like pattern within a scant to moderate amount of fibrous stroma and a few large thin-walled vascular channels. (From Stedman, 27th ed)
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
Providing an investigational therapy to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Compassionate use trials allow patients to receive promising but not yet fully studied or approved therapies when no other treatment option exists. Also called expanded access trial.
A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
Diseases of the parasympathetic or sympathetic divisions of the AUTONOMIC NERVOUS SYSTEM; which has components located in the CENTRAL NERVOUS SYSTEM and PERIPHERAL NERVOUS SYSTEM. Autonomic dysfunction may be associated with HYPOTHALAMIC DISEASES; BRAIN STEM disorders; SPINAL CORD DISEASES; and PERIPHERAL NERVOUS SYSTEM DISEASES. Manifestations include impairments of vegetative functions including the maintenance of BLOOD PRESSURE; HEART RATE; pupil function; SWEATING; REPRODUCTIVE AND URINARY PHYSIOLOGY; and DIGESTION.
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Exclusive legal rights or privileges applied to inventions, plants, etc.
Apparatus, devices, or supplies intended for one-time or temporary use.
Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, atomic number 43, and atomic weight 98.91. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.
A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.
A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities.
Inorganic salts of phosphoric acid that contain two phosphate groups.
The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
A nontoxic radiopharmaceutical that is used in the clinical evaluation of hepatobiliary disorders in humans.
A nontoxic radiopharmaceutical that is used in RADIONUCLIDE IMAGING for the clinical evaluation of hepatobiliary disorders in humans.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).
BENZOIC ACID amides.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A condition caused by dysfunctions related to the SINOATRIAL NODE including impulse generation (CARDIAC SINUS ARREST) and impulse conduction (SINOATRIAL EXIT BLOCK). It is characterized by persistent BRADYCARDIA, chronic ATRIAL FIBRILLATION, and failure to resume sinus rhythm following CARDIOVERSION. This syndrome can be congenital or acquired, particularly after surgical correction for heart defects.
Nerve fibers liberating catecholamines at a synapse after an impulse.
A device designed to stimulate, by electric impulses, contraction of the heart muscles. It may be temporary (external) or permanent (internal or internal-external).
Regulation of the rate of contraction of the heart muscles by an artificial pacemaker.
Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects.
Irregular HEART RATE caused by abnormal function of the SINOATRIAL NODE. It is characterized by a greater than 10% change between the maximum and the minimum sinus cycle length or 120 milliseconds.
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
A syndrome characterized by DYSARTHRIA, dysphagia, dysphonia, impairment of voluntary movements of tongue and facial muscles, and emotional lability. This condition is caused by diseases that affect the motor fibers that travel from the cerebral cortex to the lower BRAIN STEM (i.e., corticobulbar tracts); including MULTIPLE SCLEROSIS; MOTOR NEURON DISEASE; and CEREBROVASCULAR DISORDERS. (From Adams et al., Principles of Neurology, 6th ed, p489)
An involuntary expression of merriment and pleasure; it includes the patterned motor responses as well as the inarticulate vocalization.
A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.
Using MOLECULAR BIOLOGY techniques, such as DNA SEQUENCE ANALYSIS; PULSED-FIELD GEL ELECTROPHORESIS; and DNA FINGERPRINTING, to identify, classify, and compare organisms and their subtypes.
Persons whose profession is to give legal advice and assistance to clients and represent them in legal matters. (American Heritage Dictionary, 3d ed)
Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.
A condition in which the FORAMEN OVALE in the ATRIAL SEPTUM fails to close shortly after birth. This results in abnormal communications between the two upper chambers of the heart. An isolated patent ovale foramen without other structural heart defects is usually of no hemodynamic significance.
A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.
AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
A child who is receiving long-term in-patient services or who resides in an institutional setting.
Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES.
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.
Observable manifestations of impaired psychological functioning.

Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. (1/545)

Impaired cardiac sympathetic activity can be evaluated by 123I-metaiodobenzylguanidine (MIBG) imaging. METHODS: We studied the significance of MIBG imaging for 24 patients (age 58+/-12 y) with dilated cardiomyopathy (DCM). We compared 12 patients (group A) treated with metoprolol (dose from 30-60 mg/d) with 12 patients treated with angiotensin-converting enzyme (ACE) inhibitors. Patients were studied before treatment, after 5 mo of treatment (only in group A) and after 1 y of treatment. Cardiac MIBG uptake was assessed as the heart-to-mediastinum activity ratio (H/M) and total defect score (TDS) from anterior planar and SPECT MIBG images, which were acquired in 4 h after tracer injection. New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) calculated by echocardiography were also assessed. RESULTS: TDS decreased in both groups (in group A, from 30+/-7 through 23+/-9 to 18+/-10; P < 0.01, in group B, from 30+/-6 to 24+/-8; P < 0.01) and H/M was increased in both groups (in group A, from 1.87+/-0.31 through 2.03+/-0.28 to 2.14+/-0.29; P < 0.01, in group B, from 1.82+/-0.28 to 1.94+/-0.26; P < 0.05). But TDS and H/M were more improved in group A than in group B (P < 0.05). LVEF was significantly increased in only group A (from 38+/-6 through 43+/-8 to 49%+/-9%; P < 0.01). NYHA improved in both groups (in group A, from mean 2.5 through 2.1 to 1.8; P < 0.01, in group B, from mean 2.6 to 2.1; P < 0.05) but was more improved in group A than in group B (P < 0.05). CONCLUSION: Cardiac function, symptom and cardiac sympathetic activity evaluated by MIBG images improved after the beta-blocker therapy more than with the treatment that used ACE inhibitors.  (+info)

Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. (2/545)

Norepinephrine (NE) reuptake function is impaired in heart failure and this may participate in myocyte hyperstimulation by the neurotransmitter. This alteration can be assessed by 123I-metaiodobenzylguanidine (MIBG) scintigraphy. METHODS: To determine whether the impairment of neuronal NE reuptake was reversible after metoprolol therapy, we studied 18 patients (43+/-7 y) with idiopathic dilated cardiomyopathy who were stabilized at least for 3 mo with captopril and diuretics. Patients underwent, before and after 6 mo of therapy with metoprolol, measurements of radionuclide left ventricular ejection fraction (LVEF), maximal oxygen consumption and plasma NE concentration. The cardiac adrenergic innervation function was scintigraphically assessed with MIBG uptake and release measurements on the planar images obtained 20 min and 4 h after tracer injection. To evaluate whether metoprolol had a direct interaction with cardiac MIBG uptake and release, six normal subjects were studied before and after a 1-mo metoprolol intake. RESULTS: In controls, neither cardiac MIBG uptake and release nor circulating NE concentration changed after the 1-mo metoprolol intake. Conversely, after a 6-mo therapy with metoprolol, patients showed increased cardiac MIBG uptake (129%+/-10% versus 138%+/-17%; P = 0.009), unchanged cardiac MIBG release and decreased plasma NE concentration (0.930+/-412 versus 0.721+/-0.370 ng/mL; P = 0.02). In parallel, patients showed improved New York Heart Association class (2.44+/-0.51 versus 2.05+/-0.23; P = 0.004) and increased LVEF (20%+/-8% versus 27%+/-8%; P = 0.0005), whereas maximal oxygen uptake remained unchanged. CONCLUSION: Thus, a parallel improvement of myocardial NE reuptake and of hemodynamics was observed after a 6-mo metoprolol therapy, suggesting that such agents may be beneficial in heart failure by directly protecting the myocardium against excessive NE stimulation.  (+info)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). (3/545)

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG). (4/545)

meta-iodobenzylguanidine (MIBG) radiolabelled with iodine-131 is used for diagnosis and treatment of neuroadrenergic neoplasms such as phaeochromocytoma and neuroblastoma. In addition, non-radiolabelled MIBG, administered i.v., is used in several clinical studies. These include palliation of the carcinoid syndrome, in which MIBG proved to be effective in 60% of the patients. Oral MIBG administration might be convenient to maintain palliation and possibly improve the percentage of responders. We have, therefore, investigated the feasibility of oral administration of MIBG in an animal model. Orally administered MIBG demonstrated a bioavailability of 59%, with a maximal tolerated dose of 60 mg kg(-1). The first and only toxicity encountered was a decrease in renal function, measured by a reduced clearance of [51Cr]EDTA and accompanied by histological tubular damage. Repeated MIBG administration of 40 mg kg(-1) for 5 sequential days or of 20 mg kg(-1) for two courses of 5 sequential days with a 2-day interval did not affect renal clearance and was not accompanied by histological abnormalities in kidney, stomach, intestines, liver, heart, lungs, thymus, salivary glands and testes. Because of a sufficient bioavailability in absence of gastrointestinal toxicity, MIBG is considered suitable for further clinical investigation of repeated oral administration in patients.  (+info)

Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. (5/545)

OBJECTIVES: This prospective study was undertaken to correlate early and late metaiodobenzylguanidine (MIBG) cardiac uptake with cardiac hemodynamics and exercise capacity in patients with heart failure and to compare their prognostic values with that of peak oxygen uptake (VO2). BACKGROUND: The cardiac fixation of MIBG reflects presynaptic uptake and is reduced in heart failure. Whether it is related to exercise capacity and has better prognostic value than peak VO2 is unknown. METHODS: Ninety-three patients with heart failure (ejection fraction <45%) were studied with planar MIBG imaging, cardiopulmonary exercise tests and hemodynamics (n = 44). Early (20 min) and late (4 h) MIBG acquisition, as well as their ratio (washout, WO) were determined. Prognostic value was assessed by survival curves (Kaplan-Meier method) and uni- and multivariate Cox analyses. RESULTS: Late cardiac MIBG uptake was reduced (131+/-20%, normal values 192+/-42%) and correlated with ejection fraction (r = 0.49), cardiac index (r = 0.40) and pulmonary wedge pressure (r = -0.35). There was a significant correlation between peak VO2 and MIBG uptake (r = 0.41, p < 0.0001). With a mean follow-up of 10+/-8 months, both late MIBG uptake (p = 0.04) and peak VO2 (p < 0.0001) were predictive of death or heart transplantation, but only peak VO2 emerged by multivariate analysis. Neither early MIBG uptake nor WO yielded significant insights beyond those provided by late MIBG uptake. CONCLUSIONS: Metaiodobenzylguanidine uptake has prognostic value in patients with wide ranges of heart failure, but peak VO2 remains the most powerful prognostic index.  (+info)

Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. (6/545)

Myocardial imaging with 123I-metaiodobenzylguanidine (MIBG) was performed on 35 patients with Parkinson's disease and 24 control subjects to evaluate cardiac sympathetic function in patients with Parkinson's disease, verify this phenomenon and examine whether myocardial MIBG uptake and clearance are correlated with the clinical severity of Parkinson's disease. METHODS: We studied 35 patients with Parkinson's disease and 24 control subjects with other central nervous system diseases. The latter group consisted of 12 subjects with other neurodegenerative disorders (4 with spinocerebellar degeneration, 2 with amyotrophic lateral sclerosis, 3 with progressive supranuclear palsy and 3 with corticobasal degeneration and 12 patients with cerebral infarction (CI), 6 with vascular parkinsonism and 6 without it. Early and delayed images of the anterior view were obtained 15 min and 4 h after injection of 123I-MIBG, respectively. MIBG uptake was quantified by calculating a heart-to-mediastinum count (H/M) ratio. RESULTS: The H/M ratio was markedly reduced in the patients with Parkinson's disease (II to V on the Hoehn and Yahr scale) compared with the control subjects. None of the subjects with neurodegenerative diseases showed a marked decrease in myocardial MIBG uptake nor did any subject with CI. CONCLUSION: Our findings indicate that, in Parkinson's disease, a reduction in myocardial MIBG uptake is a very common, specific phenomenon that can be used to detect cardiac autonomic dysfunction to diagnose Parkinson's disease, particularly in patients without typical signs and symptoms.  (+info)

Myocardial stunning caused by sympathetic nerve injury after an operation on cervical vertebrae. (7/545)

In this case, electrocardiographic inverted T waves appeared after cervical laminaplasty and echocardiogram showed temporary wall motion abnormality. Myocardial metaiodobenzylguanidine (MIBG) uptake was obviously reduced in the same area where the wall motion abnormalities appeared in the echocardiogram, although no abnormalities were detected with myocardial thallium scintigraphy and coronary angiography. The myocardial stunning was caused by injury to the sympathetic nerves from a surgical procedure on the cervical vertebrae.  (+info)

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. (8/545)

OBJECTIVES: (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is clinically used to estimate local myocardial sympathetic nerve damage in some forms of heart disease, autonomic nerve disturbance in diabetic neuropathy, and disturbance of the autonomic nervous system in neurodegenerative disease. In the present study, examinations were performed to clarify (1) the proportion of cardiac sympathetic nerve disturbance in Parkinson's disease, (2) the usefulness of (123)I-MIBG myocardial scintigraphy to detect sympathetic nerve disturbances compared with autonomic function tests, (3) cardiac function in patients who have a decreased MIBG uptake in (123)I-MIBG myocardial scintigraphy, (4) the usefulness of (123)I-MIBG myocardial scintigraphy to differentiate Parkinson's disease from the other neurological diseases mimicking it. METHODS: (123)I-MIBG myocardial scintigraphy was performed, together with autonomic function tests and cardiac examinations in 46 patients with Parkinson's disease and 25 patients with vascular parkinsonism, essential tremor, or multiple system atrophy. RESULTS: In an anterior image study, the average count per pixel in heart to mediastinum (H/M) ratio decreased in 80% of the patients with Parkinson's disease in the early phase and 84% in the late phase. The mean H/M ratio in Parkinson's disease was significantly lower than that in controls and the other diseases. The H/M ratio tended to decrease with the disease progression. In almost half of the patients in Hoehn and Yahr stage I, the H/M ratio was already decreased. The sympathetic skin response in upper and lower limbs, head up tilt test, and coefficient of variation of R-R interval were abnormal in 17%, 31%, 30%, and 17% of the patients, respectively. All the patients with abnormal autonomic functions were in Hoehn and Yahr stage III, IV, or V. Echocardiography showed normal left ventricular function. Twenty four hour Holter electrocardiography detected no serious arrhythmias except for one patient with non-sustained ventricular tachycardia. CONCLUSION: (123)I-MIBG myocardial scintigraphy might detect early disturbances of the sympathetic nervous system in Parkinson's disease and might give useful diagnostic information to differentiate vascular parkinsonism, essential tremor, and multiple system atrophy from Parkinson's disease.  (+info)

In 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy, the early heart-to-mediastinum (H/M) ratio is considered to reflect the density of the cardiac sympathetic nerve endings, washout rate (WR) is an indicator of the cardiac sympathetic tone, and the delayed H/M ratio reflects both. The Delayed H/M ratio is usually used to support the diagnosis of Lewy body diseases (LBDs) and idiopathic REM sleep behavior disorder (iRBD); however, which values should be used have not been specified. Here, we hypothesized that the combination of these values is appropriate for the diagnostic purpose.In this single-center retrospective cohort study, we recruited 106 patients with LBDs or iRBD and 33 patients without those diseases, of whom we reviewed the 123I-MIBG myocardial scintigraphy results.Sensitivity/specificity to diagnose LBDs and iRBD were 0.77/0.94 for the early H/M ratio (≤ 2.0), 0.82/0.94 for the delayed H/M ratio (≤ 2.0), and 0.89/0.91 for WR (≥ 23.0). When patients were ...
TY - JOUR. T1 - Comparison of 123I-MIBG myocardial scintigraphy, brain perfusion SPECT, and voxel-based MRI morphometry for distinguishing between dementia with Lewy bodies and Alzheimers disease. AU - Inui, Yoshitaka. AU - Toyama, Hiroshi. AU - Manabe, Yuta. AU - Sarai, Masayoshi. AU - Iwata, Nakao. PY - 2014/10/16. Y1 - 2014/10/16. N2 - Objective: This study aimed to compare the diagnostic value of 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, N-isopropyl-p[123I]iodoamphetamine (IMP) brain perfusion single-photon emission computed tomography (SPECT), and brain magnetic resonance imaging (MRI) voxel-based morphometry (VBM) for the differentiation of dementia with Lewy bodies (DLB) and Alzheimers disease (AD).Methods: Thirty-five and 34 patients with probable DLB and probable AD, respectively, were enrolled. All patients underwent 123I-MIBG myocardial scintigraphy, 123I-IMP brain perfusion SPECT, and brain MRI. For 123I-MIBG imaging, we calculated early and delayed ...
TY - JOUR. T1 - Prognostic effect and modulation of cardiac sympathetic function in heart failure patients treated with cardiac resynchronization therapy. AU - Moreira, Rita Ilhão. AU - Abreu, Ana. AU - Portugal, Guilherme. AU - Oliveira, Luís. AU - Oliveira, Mário. AU - Rodrigues, Inês. AU - Cruz, Madalena Coutinho. AU - Cunha, Pedro Silva. AU - Santos, Vanessa. AU - Clara, Helena Santa. AU - Carmo, Miguel Mota. AU - Ferreira, Rui Cruz. PY - 2020/2. Y1 - 2020/2. N2 - Background: Cardiac autonomic dysfunction as assessed by 123 I-metaiodobenzylguanidine ( 123 I-mIBG) scintigraphy is associated with poor prognosis in heart failure (HF) patients. Although cardiac resynchronization therapy (CRT) has emerged as an effective therapy in improving outcomes on HF patients, its effect on cardiac sympathetic nervous function is still not fully understood. We aimed to study the value of pre-implantation 123 I-mIBG late heart-to-mediastinum ratio (HMR) as a predictor of response and outcomes after CRT ...
Background: Iodine-123-metaiodobenzylguanidine (123I-MIBG) has been used to assess function of the cardiac sympathetic nervous system in patients with chronic heart failure. Recently, we and others demonstrated that cardiac 123I-MIBG imaging represented a prognostic marker in not only systolic heart failure (SHF) patients and but also diastolic heart failure (DHF) patients. From sub-analysis of ADMIRE-HF trial, the group of SHF patients with diabetes mellitus (DM) who presented low heart to mediastinum (H/M) ratio showed poor prognosis in other groups. Epidemiologic and experimental study demonstrated that hyperglycemia facilitated myocardial diastolic dysfunction. Therefore, we examined the influence of DM on prognostic utility of cardiac 123I-MIBG imaging in DHF patients.. Methods and Results: We performed 123I-MIBG scintigraphy and echocardiography in consecutive 128 heart failure patients with left ventricular ejection fraction ≥ 50% (71 men, mean age 64±15 years) who admitted to our ...
In the present study, we found complete defects on MIBG myocardial scans in 8 of 12 patients and limited uptake in the remaining 4 in association with severe systemic autonomic dysfunction. The incidence and magnitude of myocardial accumulation of MIBG were independent of clinical findings, including neurologic disabilities, duration of the illness, extent of endomyocardial amyloid deposition, ECG QRS voltage and ventricular wall thickness. These findings strongly suggest that cardiac adrenergic denervation due to autonomic nervous degeneration ([28]) accounts for alterations in I-123 MIBG myocardial imaging in patients with familial amyloid polyneuropathy. The presence of small localized concentrations of MIBG in the LV anterior wall in some patients indicates that myocardial sympathetic innervation is not equally impaired in this disease.. As we have previously reported ([34]), Tc-99m PYP scintigraphy may have the potential to detect early myocardial amyloid infiltration in patients with ...
In heart failure secondary to chronic mechanical overload, cardiac sympathetic neurons demonstrate depressed catecholamine synthetic and transport function. To assess the potential of sympathetic neuronal imaging for detection of depressed transport function, serial scintigrams were acquired after the intravenous administration of metaiodobenzylguanidine [131I] to 13 normal dogs, 3 autotransplanted (denervated) dogs, 5 dogs with left ventricular failure, and 5 dogs with compensated left ventricular hypertrophy due to a surgical arteriovenous shunt. Nine dogs were killed at 14 hours postinjection for determination of metaiodobenzylguanidine [131I] and endogenous norepinephrine content in left atrium, left ventricle, liver, and spleen. By 4 hours postinjection, autotransplanted dogs had a 39% reduction in mean left ventricular tracer accumulation, reflecting an absent intraneuronal tracer pool. Failure dogs demonstrated an accelerated early mean left ventricular tracer efflux rate (26.0%/hour ...
Metaiodobenzylguanidine (MIBG) is a substance that is taken up by neuroblastoma or pheochromocytoma/paraganglioma tumor cells. MIBG is combined with radioactive iodine (131 I) in the laboratory to form a radioactive compound 131 I-MIBG. This radioactive compound delivers radiation specifically to the cancer cells and causes them to die.. The purpose of this research protocol is to provides a mechanism to deliver MIBG therapy when clinically indicated, but also to provide a mechanism to continue to collect efficacy and toxicity data that will be provided. ...
In connection with clinical 131I-MIBG studies of patients with suspected pheochromocytoma and adrenomedullary hyperplasia quantitative biokinetic data have been collected in order to improve the present estimations of absorbed dose to various organs and tissues. Whole-body profiles as a function of time were measured with a whole-body counter. The retention in the total body and in the thyroid gland could be derived from the measured whole-body profiles by summing up the corresponding values. The retention of 131I-MIBG could not be exactly measured for further organs from the whole-body profiles in man. For this reason animal studies were performed with mice. The biokinetic animal data were transferred to man in form of the cumulative activity for the various organs. The mean absorbed dose for selected organs per injected activity unit was calculated using the concept of absorbed fractions (MIRD method) taking into account the radioactivity within the remaining body. Except for both the adrenal medulla
Purpose: 131I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical with activity in patients with relapsed or refractory neuroblastoma. Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan.. Experimental Design: Patients 1 to 30 years old with relapsed or refractory neuroblastoma and MIBG-avid tumors were eligible. All patients had autologous hematopoietic stem cells (PBSC) available and met standard phase I organ function requirements. Irinotecan (20 mg/m2/dose IV) was given on days 0 to 4 and 7 to 11, with vincristine (1.5 mg/m2 IV) on days 0 and 7. MIBG was given on day 1 following a 3 + 3 phase I dose escalation design starting at 8 mCi/kg MIBG. PBSCs were administered at dose level 8 mCi/kg for prolonged myelosuppression and for all patients at 12 mCi/kg or more.. Results: Twenty-four patients evaluable for dose escalation (median ...
The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCT including high-dose 131I-metaiodobenzylguanidine (MIBG) treatment. In
M. Esler; Assessment of Sympathetic Nervous Function in Humans from Noradrenaline Plasma Kinetics. Clin Sci (Lond) 1 March 1982; 62 (3): 247-254. doi: https://doi.org/10.1042/cs0620247. Download citation file:. ...
131I-Metaiodobenzylguanidine (MIBG) is a guanethi-dine derivative that is structurally similar to norepi-nephrine, and therefore concentrates in the
Our findings demonstrate striking similarities in the magnitude of sympathetically mediated coronary vasodilation between the subjects with type 1 and type 2 diabetes. The results of multivariable analysis assigned an important role to the degree of cardiac sympathetic dysfunction and the duration of diabetes in predicting the MBF response to the CPT, consistent with previous results from our laboratory (6). Importantly, plasma glucose was a statistically significant predictor of the flow response to the CPT that provided incremental information above and beyond that provided by the HED retention data and the duration of diabetes. Furthermore, the presence of type 1 (insulin deficiency) or type 2 (insulin resistance) diabetes had no significant effect on the MBF response to cold, even among those without cardiac sympathetic dysfunction. Together, these findings agree and extend previous studies in healthy volunteers (10)and in subjects with impaired glucose tolerance (11). Williams et al. ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Whole-body 123I-Metaiodobenzylguanidine (mIBG) scintigraphy is used as primary image modality to visualize neuroblastoma tumours and metastases because it is the most sensitive and specific radioactive tracer in staging the disease and evaluating the response to treatment. However, especially in paediatric neuroblastoma, information from mIBG scans is difficult to extract because of acquisition difficulties that produce low definition images, with poor contours, resolution and contrast. These problems limit physician assessment. Current oncological guidelines are based on qualitative observer-dependant analysis. This makes comparing results taken at different moments of therapy, or in different institutions, difficult. In this paper, we present a computerized method that processes an image and calculates a quantitative measurement considered as its entropy, suitable for the identification of abnormal uptake regions, for which there is enough suspicion that they may be a tumour or metastatic site. This
Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. Perrone-Filardi, Pasquale; Paolillo, Stefania; Dellegrottaglie, Santo; Gargiulo, Paola; Savarese, Gianluigi; Marciano, Caterina; Casaretti, Laura; Cecere, Milena; Musella, Francesca; Pirozzi, Elisabetta; Parente, Antonio; Cuocolo, Alberto // Heart;Nov2011, Vol. 97 Issue 22, p1828 Cardiac sympathetic activity can be assessed by 123I-labelled meta-iodobenzylguanidine (MIBG) scintigraphy. Abnormalities of sympathetic cardiac activity have been shown in patients with heart failure, resulting in reduced MIBG uptake. Abnormal MIBG uptake predicts cardiac death, arrhythmias and... ...
Myocardial cells obtain 60-90% of their energy from free fatty acids under aerobic conditions. 123I-BMIPP can demonstrate fatty acid metabolism in the myocardium and is used to evaluate cardiac diseases. Forty-three patients underwent BMIPP imaging in the early (15min) and delayed (4hr) phase, and the washout rate was calculated. We evaluate the washout rate by two methods, the polar map method and the planar image method. The two methods showed close correlation (r=0.473 ...
According to recent studies, lung uptake of iodine-123-metaiodobenzylguanidine (123I-MIBG) is impaired in many lung diseases and low lung uptake of 123I-MIBG suggests endothelial dysfunction of the pulmonary artery. 123I-MIBG scintigraphy in patients with pulmonary hypertension (PH) has not yet been clinically evaluated. We hypothesized that the lung uptake of 123I-MIBG is reduced in patients with PH and differs among PH subtypes. The purpose of the present study was to analyze the lung uptake of 123I-MIBG in patients with PH and compare it with the data obtained by echocardiography or right heart catheterization ...
Duke Childrens offers the latest treatments for children with neuroblastoma including a new targeted treatment called I-131 MIBG therapy.
Some patients are at risk for life-threatening fast heart rates. These can frequently be treated by using a catheter inside the heart to burn away the cells
TY - JOUR. T1 - Influence of age and gender on iodine-123 MIBG kinetics in normal lung. AU - Kanzaki, Noriko. AU - Soda, Ryo. AU - Takahashi, Kiyoshi. AU - Sato, Keiko. AU - Hayabara, Toshiyuki. AU - Kibata, Masayoshi. AU - Takeda, Yoshihiro. AU - Hiraki, Yoshio. PY - 1998/1/1. Y1 - 1998/1/1. N2 - Iodine-123 MIBG is a biochemical marker that can be used to monitor pulmonary norepinephrine (NE) metabolism. The purpose of this study was to characterize pulmonary I-123 MIBG kinetics in relation to age and gender. Materials and Methods: Seventeen healthy volunteers and 14 patients with no cardiac or pulmonary disorders were included in this study (age range: 24 to 88 years, mean age 50.2 ± 17.6 years; 16 males, 15 females). Planar images were obtained 15 min (early) and 3 h (delayed) after injection of I-123 MIBG (111 MBq). Pulmonary uptake of I-123 MIBG was quantified based on the lung- to-mediastinum ratio (LMR) on early and delayed images. The lung clearance rate (LCR) was calculated from both ...
I-131 MIBG. Information for Physicians. AnazaoHealth, Nuclear Medicine Division, understands that your patients treatment needs are very specific. We will compound to your precise prescription, allowing you the flexibility of providing either I-131 MIBG or I-123 MIBG in your specified dose (mCi).. AnazaoHealth can provide I-131 MIBG five days a week. I-123 MIBG is available Tuesday through Thursday.. Please contact AnazaoHealth for information about these products.. ...
The aim of this review is to describe the role of nuclear imaging modalities using different radiotracers such as labeled nor-cholesterol, metaiodobenzylguanidine (MIBG) and deoxy-glucose (FDG) in the diagnostic evaluation of patients with adrenal tumours to perform lesion characterization in comparison with MR imaging.
Image of neuroblastoma using the radiopharmaceutical metaiodobenzylguanidine. The arrows identify areas of drug uptake to identify metasta
Click on this photo to see a day-by-day look at Simons MIBG therapy hospital stay. Thursday brought a real highlight: a visit by childrens author and storytime librarian Shutta Crum. Shutta read from her new book Fox and Fluff and from a family favorite All On A Sleepy Night. Thanks, Shutta!. After 4 nights in the General Clinical Research Center at the UM Hospital, Simon came home today! He was injected on Tuesday, November 5 with a high dose of I-131 MIBG (18 mCi/kg). Over the next 3 days, his body emited a rapidly decreasing amount of radioactivity, and he was cleared today to leave his cell-like hospital room.. The hardest part was having a foley catheter in place from Monday morning until Friday morning. As one of his caregivers put it, Big catheter, small penis. Simon suffered a lot of discomfort from the catheter, which was alleviated somewhat by a numbing gel (litocane) and drowsiness-inducing medications like benadryl. Since the body eliminates the radiocative substance ...
Well this is awkward... I think its been 12.. days, I dont even know quite honestly, Im completely disconnected from the world right now. I kind of left all of you hanging, I apologize for my absence. I was just having MIBG radiotherapy, no big deal, my tumours havent been very happy with me that I…
H&Ms business concept is to offer fashion and quality at the best price in a sustainable way. H&M has since it was founded in 1947 grown into one of the worlds leading fashion companies. The content of this site is copyright-protected and is the property of H&M Hennes & Mauritz AB. ...
The best Organ lessons in Camp H M Smith, HI as rated by students. Browse Camp H M Smith Organ teachers - ask questions, read reviews & compare rates!
abstractNote = {In Churg-Strauss syndrome (CSS) it is important to detect cardiac involvement, which predicts poor prognosis. This study evaluated whether {sup 123}I-metaiodobenzylguanidine (MIBG) scintigraphy could detect cardiac damage and predict cardiac events in CSS. {sup 123}I-MIBG scintigraphy was performed in 28 patients with CSS, 12 of whom had cardiac involvement. The early and delayed heart to mediastinum ratio (early H/M and delayed H/M) and washout rate were calculated by using {sup 123}I-MIBG scintigraphy and compared with those in control subjects. Early H/M and delayed H/M were significantly lower and the washout rate was significantly higher in patients with cardiac involvement than in those without and in controls (early H/M, p = 0.0024, p = 0.0001; delayed H/M, p = 0.0002, p = 0.0001; washout rate, p = 0.0012, p = 0.0052 vs those without and vs controls, respectively). Accuracy for detecting cardiac involvement was 86% for delayed H/M and washout rate and 79% for early H/M and ...
Background: Left cardiac sympathetic denervation (LCSD) suppresses ventricular arrhythmias (VAs), and reduces the incidence of sudden cardiac death (SCD). The role of bilateral cardiac sympathetic denervation (BCSD) remains unknown. The purpose of this study was to report the effects of BCSD in a small patient cohort.. Methods: We reviewed records of 6 patients (5 males, age 47-75 years, 66.7% non-ischemic cardiomyopathy) who underwent BCSD to treat severe VAs refractory to all other treatment modalities. Reversible causes of VAs were addressed in all patients. All patients were on beta-blocker therapy, and at least one antiarrhythmic drug. Five patients underwent catheter mapping with endocardial and/or epicardial ablation to control VAs (mean 2.2±0.5 ablations/patient). VAs persisted in 3 patients despite prior LCSD. Surgical BCSD was successfully performed in all patients (50% simultaneously, 50% right cardiac sympathetic denervation after prior unsuccessful LCSD).. Results: After BCSD, mean ...
TY - JOUR. T1 - Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma. T2 - A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. AU - Di Giannatale, Angela. AU - Dias-Gastellier, Nathalie. AU - Devos, Annick. AU - Mc Hugh, Kieran. AU - Boubaker, Ariane. AU - Courbon, Frederic. AU - Verschuur, Arnaud. AU - Ducassoul, Stéphane. AU - Malekzadeh, Katty. AU - Casanova, Michela. AU - Amoroso, Loredana. AU - Chastagner, Pascal. AU - Zwaan, Christian M.. AU - Munzer, Caroline. AU - Aerts, Isabelle. AU - Landman-Parker, Judith. AU - Riccardi, Riccardo. AU - Le Deley, Marie Cecile. AU - Geoerger, Birgit. AU - Rubie, Hervé. PY - 2014/1. Y1 - 2014/1. N2 - Purpose To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma. Patients and Methods This multicenter, non-randomised, phase II study included children ...
The Specific Aim #1 of this study is to assess, with 123iodine metaiodobenzylguanidine (123I-MIBG imaging), whether cardiac resynchronization therapy (CRT) rebalances and improves the integrity and function of sympathetic nerve terminals in the failing myocardium. The study will test the hypothesis that resynchronization of biventricular contractility attenuates excessive sympathetic drive, and improves autonomic function and cardiac performance.. The Specific Aim #2 of this study is to determine the relationship between 123I-MIBG labeling of sympathetic activity and physiological measures of cardiopulmonary and autonomic function. This aim is to test the hypothesis that impaired cardiac sympathetic activity, determined by 123I-MIBG imaging will be associated with poorer submaximal exercise gas exchange (higher ventilation - carbon dioxide (CO2) slopes, low end tidal CO2, reduced oxygen pulse and a more rapid frequency response) as well as reduced heart rate power spectral frequencies, a blunted ...
TY - JOUR. T1 - Both central command and exercise pressor reflex activate cardiac sympathetic nerve activity in decerebrate cats. AU - Tsuchimochi, Hirotsugu. AU - Hayes, Shawn G.. AU - McCord, Jennifer L.. AU - Kaufman, Marc P. PY - 2009/4. Y1 - 2009/4. N2 - Both static and dynamic exercise are known to increase cardiac pump function as well as arterial blood pressure. Feedforward control by central command and feedback control by the exercise pressor reflex are thought to be the neural mechanisms causing these effects during exercise. It remains unknown as to how each mechanism activates cardiac sympathetic nerve activity (CSNA) during exercise, especially at its onset. Thus we examined the response of CSNA to stimulation of the mesencephalic locomotor region (MLR, i.e., central command) and to static muscle contraction of the triceps surae muscles or stretch of the calcaneal tendon in decerebrate cats. We found that MLR stimulation immediately increased CSNA, which was followed by a gradual ...
Parkinsons disease (PD) with autonomic dysfunction is difficult to differentiate from Parkinsonism-predominant multiple system atrophy (MSA-p). This study aimed to analyze the validity of MIBG scintigraphy for PD with autonomic dysfunction and MSA-p
Study Type: Pilot/interventional. Study Title: 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study. Study Sponsor and Collaborators: University of California, San Francisco. Purpose: To describe organ dosimetry and acute toxicities using no carrier added and carrier added 124I-MIBG PET/CT in patients with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG. Eligible Ages: 3 years or older. Eligible Genders: Both. Accepts Healthy Volunteers: No. Primary Outcome Measures: • Measurements of organ dosimetry using high specific activity (no carrier added) 124I-MIBG PET/CT (time frame: PET/CT scans on days 0-week 7). • Measurements of organ dosimetry using low specific activity (carrier added) 124I-MIBG PET/CT (time frame: PET/CT scans on days 0-week 7). • Change from baseline of blood pressure measurements at week 7 (time frame: safety assessments on days 0- week 7). • ...
A Guanidine analog with specific affinity for Tissues of the Sympathetic Nervous System and related Tumors. The radiolabeled Forms are used as Antineoplastic Agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a Neuron-blocking agent which has a strong affinity for, and Retention in, the Adrenal Medulla and also inhibits ADP-Ribosyltransferase ...
18F-N-[3-bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (18F-LMI1195) is a new class of PET tracer designed for sympathetic nervous imaging of the heart. The favorable image quality with high and specific neural uptake has been previously demonstrated in animals and humans, but intracellular behavior is not yet fully understood. The aim of the present study is to verify whether it is taken up in storage vesicles and released in company with vesicle turnover. Both vesicle-rich (PC12) and vesicle-poor (SK-N-SH) norepinephrine-expressing cell lines were used for in vitro tracer uptake studies. After 2 h of 18F-LMI1195 preloading into both cell lines, effects of stimulants for storage vesicle turnover (high concentration KCl (100 mM) or reserpine treatment) were measured at 10, 20, and 30 min. 131I-meta-iodobenzylguanidine (131I-MIBG) served as a reference. Both high concentration KCl and reserpine enhanced 18F-LMI1195 washout from PC12 cells, while tracer retention remained stable in the SK-N-SH cells. After
Background: \(^{18}\)F-N-[3-bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (\(^{18}\)F-LMI1195) is a new class of PET tracer designed for sympathetic nervous imaging of the heart. The favorable image quality with high and specific neural uptake has been previously demonstrated in animals and humans, but intracellular behavior is not yet fully understood. The aim of the present study is to verify whether it is taken up in storage vesicles and released in company with vesicle turnover. Results: Both vesicle-rich (PC12) and vesicle-poor (SK-N-SH) norepinephrine-expressing cell lines were used for in vitro tracer uptake studies. After 2 h of \(^{18}\)F-LMI1195 preloading into both cell lines, effects of stimulants for storage vesicle turnover (high concentration KCl (100 mM) or reserpine treatment) were measured at 10, 20, and 30 min. \(^{131}\)I-meta-iodobenzylguanidine (\(^{131}\)I-MIBG) served as a reference. Both high concentration KCl and reserpine enhanced \(^{18}\)F-LMI1195 washout from PC12 ...
Background: \(^{18}\)F-N-[3-bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (\(^{18}\)F-LMI1195) is a new class of PET tracer designed for sympathetic nervous imaging of the heart. The favorable image quality with high and specific neural uptake has been previously demonstrated in animals and humans, but intracellular behavior is not yet fully understood. The aim of the present study is to verify whether it is taken up in storage vesicles and released in company with vesicle turnover. Results: Both vesicle-rich (PC12) and vesicle-poor (SK-N-SH) norepinephrine-expressing cell lines were used for in vitro tracer uptake studies. After 2 h of \(^{18}\)F-LMI1195 preloading into both cell lines, effects of stimulants for storage vesicle turnover (high concentration KCl (100 mM) or reserpine treatment) were measured at 10, 20, and 30 min. \(^{131}\)I-meta-iodobenzylguanidine (\(^{131}\)I-MIBG) served as a reference. Both high concentration KCl and reserpine enhanced \(^{18}\)F-LMI1195 washout from PC12 ...
Neuroblastoma is a highly malignant tumor of children that arises in the peripheral sympathetic nervous system, and spreads widely to bones and bone marrow. The survival of children with metastatic neuroblastoma is less than 40%, despite intensive chemotherapy, radiation and bone marrow transplant. Metaiodobenzylguanidine (MIBG) is a chemical similar in structure to noradrenaline and specifically taken up by neuroblastoma, thus providing a means to detect tumor metastases and to deliver intravenous tumor-targeted radiation by attaching a radioactive iodine molecule. 131I-MIBG has achieved responses of 40% in children with relapsed neuroblastoma, with very few side effects, but due to the special requirements of administering radioactive medicines, is used at only a few centers and is not yet approved for commercial use by the FDA. Furthermore, there is very little pre-clinical data on using MIBG in combination with the new molecularly targeted drugs to provide a platform for overcoming resistant ...
The validation procedure using both features, ROIt1 and ROIt2, provided a very good classification accuracy. RF, in addition to classification also computed a percent level of confidence for the assigned class for each subject. This allowed the partition of the feature plane in high and low level of classification confidence for the two classes. The feature plane had been divided in 4 macroregions with different degree of confidence in the classification: region A-PD (high confidence), region B- PS/ET (high confidence), region C-D for both classes (low confidence). A separation threshold between the most confidence regions resulted about 1.55 for both ROIt1 and ROIt2, thus meaning that pts with uptake values lower 1.55 were classified as PD, while higher value as PS or ET. Globally, RF permitted to achieve a classification pt performance of 98.5% using ROIt1 and ROIt2 of 97.5% using only ROIt1 and 95.5% using only ROIt2, both the selected features being effective in distinguishing the difference ...
Sudomotor dysfunction testing may indicate to physicians of a patients peripheral nerve and cardiac sympathetic dysfunction. To learn more Contact Us.
I met with Lisas doctor last Thursday before her last dose of chemo of round four. We talked about what to expect during and after her MIBG Therapy scheduled for April 26. The 26th will mostly be prepping her for the Therapy that will begin on the 27th. On the 27th shell begin her treatment which will isolate her for at least 36 hours because she will be so radioactive. During those 36 hours only the medical personnel are able to enter the room in full hazmat gear to take vitals and give meds and chemo. Yes, on top of the MIBG Therapy Lisa will be receiving her 5th round of chemo. After 36 hours the level of radiation emanating from Lisa should be low enough for Linda and I to go in for short visits. After another 36 hours levels should be low enough for her to discharged. Once home with her we can expect to experience all the normal side effects of chemo and radiation treatment. Were cautioned that while we can resume our usual lifestyle, we should not sit for prolonged periods with Lisa ...
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. 61 ...
MIBG has been tested in clinical trial in the US for several years now. However, it has only been offered in a few locations throughout the US. This is a huge problem as many believe that this is a treatment that should be potentially available to every high risk neuroblastoma patient as a part of upfront therapy. I can tell you from my perspective that I have seen MIBG therapy be the single treatment capable of bringing some kids into remission. When all else failed, MIBG was the treatment that has saved some kids lives ...
Àhámọ́ jẹ́ ẹyọ aládìmú àti oníàmúṣe fún gbogbo àwọn ohun ẹlẹ́ẹ̀mì tí a mọ̀. Òhun ni ẹyọ ẹ̀mí tó kéréjùlọ tó jẹ́ tòsọ́tọ̀ bí i ohun alàyè, wọ́n sì tún ùnpé bíi òkúta ìkọ́ ẹ̀mí.[1] Àwọn ohun ẹlẹ́ẹ̀mí ṣe é tòsọ́tọ̀ bíi oníàhámọ́kan (consisting of a single cell; èyí kàkún ọ̀pọ̀ àwọn baktéríà) tàbí oníàhámọ́púpọ̀ (èyí kàkún àwọn ọ̀gbìn àti ẹranko). Ara àwọn ọmọ ènìyàn ní bíi ẹgbẹgbẹ̀rúnkẹta 100 àhámọ́; ìtóbi àhámọ́ jẹ́ 10 µm nígbàtí ìkórajọ àhámọ́ jẹ́ 1 nanogram. ...
This is the only in-depth, single author survey of heart development. It will provide a more systematic, up-to-date synthesis of the subject than any other volume, spanning the range from classical anatomical studies to recent findings in molecular biology. It also covers topics that are often omitted from discussions of heart development, such as myocardial function, cardiac innervation, and conduction development and clinical correlates will be discussed throughout.
This is the only in-depth, single author survey of heart development. It will provide a more systematic, up-to-date synthesis of the subject than any other volume, spanning the range from classical anatomical studies to recent findings in molecular biology. It also covers topics that are often omitted from discussions of heart development, such as myocardial function, cardiac innervation, and conduction development and clinical correlates will be discussed throughout.
Index of immune sensitivity (IS) of tumor cells was determined as the difference between values of log TrD50 for immune and normal animals.. The specific immunization of animals within the first 60-70 days was highly efficient and prevented the appearance of SV40 tumors in 90-100% of the animals (Fig. 5, grey columns). However, the efficiency of immune tumor prevention rapidly decreased on the 90-100th days of the latent period and was inefficient from the first day after the end of the minimal latent period (although it was long before the peak of appearance of the primary tumors) [66-68].. Thus, the period of maximal efficiency of the preventive specific immunization against the SV40 primary tumors (the first 60-70 days of the latent period) was strikingly the same as the early [H2O2CA + PGES] phenotype-negative stage in the development of these tumors when they could not yet protect themselves. And, on the contrary, the end of this naive stage (within 60-100 days of the latent period) ...
H&Ms business concept is to offer fashion and quality at the best price in a sustainable way. H&M has since it was founded in 1947 grown into one of the worlds leading fashion companies. The content of this site is copyright-protected and is the property of H&M Hennes & Mauritz AB. ...
5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole MeSH D02.640.600.290 - fanft MeSH D02.640.600.308 - furagin MeSH D02.640. ... 3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide MeSH D02.092.146.325 - p-dimethylaminoazobenzene MeSH D02.092. ... vitamin k 3 MeSH D02.455.849.291.850 - taxoids MeSH D02.455.849.291.850.777 - paclitaxel MeSH D02.455.849.365 - dolichol MeSH ... 3-diketogulonic acid MeSH D02.241.081.844.300 - glucaric acid MeSH D02.241.081.844.322 - gluconates MeSH D02.241.081.844. ...
"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy" (PDF). 17 June 2009. Archived from the ... 851-3 Greenwood and Earnshaw, pp. 853-9 Greenwood and Earnshaw, pp. 863-4 Greenwood and Earnshaw, pp. 872-5 Greenwood and ... 88 (3): 265-91. doi:10.1515/pac-2015-0305. Magnetic susceptibility of the elements and inorganic compounds, in Handbook of ... In biology, linoleic acid (C18:2 n-6), omega-6 and alpha-linolenic (C18:3 n-3) omega-3, arachidonic acid (AA) - omega-6 (C20: ...
Iodobenzylguanidine. J Nucl Med 25:2-6, 1984 Carpi, Angelo; Mechanick, Jeffrey I. (2016). Thyroid Cancer: From Emergent ... 81 (8): 2930-3. doi:10.1210/jc.81.8.2930. PMID 8768854. Lawrence, J. E.; Lamm, S. H.; Pino, S.; Richman, K.; Braverman, L. E. ( ... The majority of I-131 will be eliminated from the human body in 3-5 days, through natural decay, and through excretion in sweat ... 1 (3): 197-203. doi:10.1023/A:1010031115233. ISSN 1389-9155. PMID 11705004. S2CID 13575769. Frot, Jacques. "The Causes of the ...
Another way to detect neuroblastoma is the meta-iodobenzylguanidine scan, which is taken up by 90 to 95% of all neuroblastomas ... ISBN 978-3-540-26616-7. Beckwith JB, Perrin EV (December 1963). "In Situ Neuroblastomas: A Contribution to the Natural History ... 115 (3-4): 273-82. doi:10.1159/000095924. PMID 17124410. S2CID 14012430. Carén H, Erichsen J, Olsson L, Enerbäck C, Sjöberg RM ... Stage 3: Tumor infiltrating across midline with or without regional lymph node involvement; or unilateral tumor with ...
I131-MIBG (m-iodobenzylguanidine) Neuroectodermal tumor imaging IV In-vivo Imaging TherapeuticEdit. Name Treatment of Route of ... I123-MIBG (m-iodobenzylguanidine) Neuroectodermal tumour imaging IV In-vivo Imaging I123-FP-CIT SPECT imaging of Parkinson's ... Hydrogen-3Edit. 3H or tritium is a beta emitter. Name Investigation Route of administration In-vitro / in-vivo Imaging / non- ...
... meta-iodobenzylguanidine (MIBG) imaging for neuroendocrine tumors, heat-damaged red blood cell imaging for identifying ectopic ... 1996 Jul;26(3):191-193. PMID 8829280. PET center of excellence ABNM brochure Archived 2007-07-01 at the Wayback Machine nuclear ...
Iodine-123-meta-iodobenzylguanidine myocardial scintigraphy can help find denervation of the nerves around the heart, which can ... 9 Suppl 3 (Suppl 3): 23-30. doi:10.1046/j.1468-1331.9.s3.3.x. PMID 12464118. Gibb WR, Lees AJ (June 1988). "The relevance of ... Males are more often affected than females at a ratio of around 3:2. When it is seen in people before the age of 50, it is ... Davis P (3 May 2007). "Michael J. Fox". The TIME 100. Time. Archived from the original on 25 April 2011. Retrieved 2 April 2011 ...
Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging. The safety and scientific validity of this study ... 3-Iodobenzylguanidine. Anti-Infective Agents, Local. Anti-Infective Agents. Trace Elements. Micronutrients. Growth Substances. ... and 3) by performing a special heart scan. ...
2-(2-Iodobenzyl)guanidine *Molecular FormulaC8H10IN3. *Average mass275.090 Da ...
3-Iodobenzylguanidine. Anti-Infective Agents, Local. Anti-Infective Agents. Trace Elements. Micronutrients. Growth Substances. ...
I 131 Meta-iodobenzylguanidine. *I-131 Metaiodobenzylguanidine. *Iobenguane (131I). *Iobenguane I 131 ... A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly ... Event free survival (EFS) (Arm A, B, D, and E) [ Time Frame: 3 years ]. EFS time is calculated from date of randomization or ... After completion of study therapy, patients in Arms A-D are followed up every 3 months for 18 months, and then every 6 months ...
3-Iodobenzylguanidine. Anti-Infective Agents, Local. Anti-Infective Agents. Trace Elements. Micronutrients. Nutrients. Growth ... The catheter will be removed 3-5 days following the treatment. General anesthesia or sedation is typically given for the ...
This paper describes the methodology which can be used to determine whole-body, red marrow, blood, bladder, liver, and tumour doses delivered during 131I-mIBG therapy of neuroblastoma. The methodology is based on the Physics Protocol used in a multi-centre study undertaken by the United Kingdom Chil …
Two recently developed radiopharmaceuticals, iodine-131 metaiodobenzylguanidine (MIBG) and indium-111 pentetreotide, are currently being used for the diagnosis and therapy of neural crest tumours by interaction with the characteristic features of these tumours, such as an active uptake-1 mechanism a …
Smets L. A., Bout B., Wisse J. Cytotoxic and antitumour effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG ... m-iodobenzylguanidine and methylglyoxal bis (guanylhydrazone). Biochem. Pharmacol., 42: 793-798, 1991. ... m-iodobenzylguanidine; MRP, MDR-associated protein; MTT, 3-(4,5-dimethylthiazolyl)-2,5-diphenyl tetrazolium bromide; Pgp, P- ... 3A) ⇓ . The dose of 20 mg/kg tended to delay tumor growth for the first 3 weeks of treatment, but, thereafter, tumor growth ...
Received Day: 22 Month: 3 Year: 2012. Accepted Day: 25 Month: 6 Year: 2012. Electronic publication date: Day: 18 Month: 7 Year ... 3). Also, the wash-out rate was significantly higher in these patients (−3.3 ± 9.9 % vs. 17 ± 10 %, p , 0.001; Fig. 4). There ... 3.. Klein AL,Hatle LK,Taliercio CP,Taylor CL,Kyle RA,Bailey KR,et al. Serial Doppler echocardiographic follow-up of left ... Table 3 summarizes the echocardiographic examination results. Left and right ventricular wall thickness was overall normal in ...
3-Iodobenzylguanidine / diagnostic use*. Adenosine / diagnostic use. Aged. Autonomic Nervous System Diseases / etiology*. ...
f) electron deficient aromatic rings suitable for nucleophilic iodination, such as hippurate and 2-iodobenzylguanidine. ... Preferred tropane derivatives are 123I-CIT (Dopascan™), 123I-CTT-FP (DaTSCAN™) and the E isomer of 123I-2β-carbomethoxy-3 β-(4- ... Such reaction vessels are preferably 1 to 10 cm3, most preferably 2 to 5 cm3 in volume and are configured such that 3 or more ... The method of any one of Claims 1 to 3, where the biological targeting molecule is chosen from: a tropane, a fatty acid, a ...
EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35(5):1039-47 ... Table 3 Summary of reported cases of therapeutic radiopharmaceutical extravasation. Full size table. ... 3.. Silberstein EB, Buscombe, J.R., McEwan, A., Taylor, A.T.Jr.,.Society of Nuclear Medicine Procedure Guideline for Palliative ... 42-44]. Particularly the long period of 2 and 3 years after 201Th-thallous chloride raise questions whether the skin lesions ...
Phosphoric Acids: 3*Phosphates: 1226*Polyphosphates: 112*Diphosphates: 62*Technetium Tc 99m Pyrophosphate: 172*technetium Tc ... 3. Amyloidosis 07/01/1993 - "[Technetium TC 99m pyrophosphate myocardial scintigraphy in amyloidosis. ". 01/01/1990 - "Soft- ... 99mTc-Pyrophosphate; Diphosphoric Acid, Technetium Salt; Tc-PYP; Technetium Tc 99m Pyrophosphate, Tc(3+) Salt (3:4); Technetium ...
3. Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/2012 - 06/2005. 3. Rhabdoid Tumor (Rhabdoid Tumors) 09/2011 - 09/2004 ... 3-Iodobenzylguanidine (Iobenguane)IBA 07/2012. 1. 6- acetyl- 8- cyclopentyl- 5- methyl- 2- (5- piperazin- 1- ylpyridin- 2- ... ylamino)- 8H- pyrido(2,3- d)pyrimidin- 7- oneIBA 09/2011. ...
6 weeks must have elapsed since treatment with therapeutic doses of M-Iodobenzylguanidine (MIBG); ,= 3 months must have elapsed ... Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =, 135 U/L (3 x ULN) (for the purpose of this ... Patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 ... Central line placement or subcutaneous port placement is not considered major surgery but must be placed at least 3 days prior ...
Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine. Gene Ther 1999;6(6):1147-52 ... Prostate 2011;71(3):281-8. *Hope TA, Aggarwal R, Chee B, et al. Impact of 68Ga-PSMA-11 PET on management in patients with ... After administration into the bloodstream, 177Lu-PSMA-617 binds to prostate cancer cells that express PSMA13, a transmembrane ... VISION: an international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of ...
123I-meta-iodobenzylguanidine (123I-MIBG) as an imaging marker.10 We also assessed the alterations in regional myocardial ... after an intravenous infusion of 5 mCi 123I-meta-iodobenzylguanidine (123I-MIBG) before and after pacemaker implantation. A ... Volume 88, Issue 3 *Assessment of myocardial adrenergic innervation in patients with sick sinus syndrome: effect of ... They had a four minute intravenous infusion of dipyridamole, 0.56 mg/kg body weight, and three minutes later 3 mCi of thallium ...
The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma. Eur J Nucl Med 1988; 13:574- ... 3.. Atkins H, Robertson J, Croft B et al. MIRD dose estimate report no. 9: radiation absorbed dose estimates for radioxenons in ... 3: radiation absorbed dose estimates for technetium-99m sulfur colloid in various liver conditions. J Nucl Med 1975;16:108A- ... Stabin M, Taylor A Jr, Eshima D, Wooten W. Radiation dosimetry for technetium-99m-MAG3, technetium-99m-DTPA, and iodine-131 OIH ...
resveratrol: 3 outcomes 10 studies in 53 results : IBA. *Glucagon-Like Peptide 1 (GLP 1): 3 outcomes 9 studies in 18 results : ... PPAR gamma: 3 outcomes 1 study in 16 results : IBA. *Excitatory Amino Acid Antagonists: 3 outcomes 1 study in 11 results : IBA ... catalpol: 3 outcomes 5 studies in 13 results : IBA. *Nitric Oxide (Nitrogen Monoxide): 3 outcomes 4 studies in 165 results : ... 3-Iodobenzylguanidine (Iobenguane): 1 outcome 1 study in 9 results : IBA. *tauroursodeoxycholic acid: 1 outcome 1 study in 9 ...
Iodobenzylguanidine Sulfate (123I). m-(123I)Iodobenzylguanidine. m-Iodobenzylguanidine-123I. MIBG-I-123. ...
A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine) is injected into a vein. Later that day (or the next day) you lie on ... You may be asked to return for repeated scans for 1 - 3 days. Each scan takes 1 - 2 hours. ... The person must be able to return for delayed images within 1 - 3 days. ...
meta-iodobenzylguanidine. NYHA. New York Heart Association. PET. positron emission tomography. SCD. sudden cardiac death. SPECT ... 5) (23) and/or SPECT imaging with metaiodobenzylguanidine (mIBG) labeled with radioactive iodine (123I) (24) or by positron ... Example of the heart to mediastinum (H/M) ratio calculated from a [123I]meta-iodobenzylguanidine planar anterior image. (A) ... Sudden cardiac death rates by [123I]meta-iodobenzylguanidine washout rate (WR) ,27% (abnormal) versus ≤27% (normal). (A) ...
The biodistribution of no-carrier-added (n.c.a.) meta-[131I]iodobenzylguanidine ([131I]MIBG) and that prepared by the standard ... An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to ... Humans (3)3-Iodobenzylguanidine (2)Antineoplastic Agents (2)Iodobenzenes (2)Mice, Inbred BALB C (2)Myocardial Contraction (2) ... 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. Larsen ...
An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to ... 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.  ...
iodine-123-meta-iodobenzylguanidine. STE. ST-segment elevation. TTC. takotsubo cardiomyopathy. TTE. transthoracic ... Iodine-123-meta-iodobenzylguanidine. In the TTC group, subacute and follow-up examinations were performed 8 days (range 6 to 10 ... Scintigraphic iodine-123-meta-iodobenzylguanidine (mIBG) imaging of the heart and measurement of plasma catecholamines can be ... Iodine-123-meta-iodobenzylguanidine (mIBG) is a gamma-emitting norepinephrine analogue that shares the same presynaptic uptake ...
Meta-iodobenzylguanidine uptake was normal in the 4 investigated patients. Clinical and imaging findings of 3 CADASIL patients ... Brain MRI and 123I-FP-CIT SPECT studies were performed in all subjects and myocardial 123I-meta-iodobenzylguanidine (MIBG) ... 123I-meta-iodobenzylguanidine myocardial scintigraphy resulted to be normal in the 4 investigated patients, contributing to ... Myocardial 123I-meta-iodobenzylguanidine scintigraphy resulted normal. Nigrostriatal denervation was also demonstrated in 2 ...
I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent , Patient medical information and education container , Ether ... New thieno[2,3-b] pyrrole compounds of the formula: ##STR1## in which: R.sub.1 is hydrogen or lower alkyl, R.sub.2 is cyano, ... I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent. A novel compound, 4-amino-3-iodobenzylguanidine, in ... Antimigraine 8-[3-(4-aminocarbonyl piperazino and piperidino) propyl[xanthines. Xanthine compounds of the formula: ##STR1## in ...
Cardiac neurotransmission imaging with 123I-meta-iodobenzylguanidine in postural tachycardia syndrome. Journal of Neurology, ... 3.. Sousa, J., El-Atassi, R., Rosenheck, S., Calkins, H., Langberg, J., & Morady, F. (1991). Radiofrequency catheter ablation ... After an initial symptom-free period (3-6 weeks) post ablation each patient began to experience symptoms of orthostatic ...
A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. ... Adrenal medullary imaging; Meta-iodobenzylguanidine scintiscan; Pheochromocytoma - MIBG; Neuroblastoma - MIBG; Carcinoid MIBG ... You may need to return for repeated scans for 1 to 3 days. Each scan takes 1 to 2 hours. ...
No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot. 1993;44(3):621-8.Google Scholar ... A convenient method for the preparation of radioiodinated meta-iodobenzylguanidine at a no-carrier-added level. J Labelled ... Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma. J Radioanal Nucl ... 3.. Racys DT, Sharif SA, Pimlott SL, Sutherland A. Silver(I)-catalyzed iodination of Arenes: tuning the Lewis acidity of N- ...
  • All patients underwent myocardial imaging with planar and single photon emission computed tomography (SPECT) after an intravenous infusion of 5 mCi 123 I-meta-iodobenzylguanidine ( 123 I-MIBG) before and after pacemaker implantation. (bmj.com)
  • In our study, we evaluated the adrenergic innervation of the left ventricle in patients with sick sinus syndrome using the radioionated noradrenaline (norepinephrine) analogue, 123 I-meta-iodobenzylguanidine ( 123 I-MIBG) as an imaging marker. (bmj.com)
  • A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine) is injected into a vein. (uclahealth.org)
  • The biodistribution of no-carrier-added (n.c.a.) meta-[131I]iodobenzylguanidine ([131I]MIBG) and that prepared by the standard isotopic exchange method were compared in athymic mice bearing SK-N-SH human neuroblastoma xenografts. (duke.edu)
  • An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to possess many properties similar to those of the parent compound. (duke.edu)
  • Iodine-123 (I-123) meta-iodobenzylguanidine (MIBG) imaging was performed in 31 patients. (naver.com)
  • Inverse relationship between cardiac accumulation of meta-[131I]iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. (naver.com)
  • IMSEAR at SEARO: Differentiation of dementia with Lewy bodies, Alzheimer's disease and vascular dementia by cardiac 131I-meta-iodobenzylguanidine (MIBG) uptake (preliminary report). (who.int)
  • Jindahra P, Vejjajiva A, Witoonpanich R, Sirisriro R, Sritara C, Pulkes T. Differentiation of dementia with Lewy bodies, Alzheimer's disease and vascular dementia by cardiac 131I-meta-iodobenzylguanidine (MIBG) uptake (preliminary report). (who.int)
  • Among these techniques 123I-meta-iodobenzylguanidine (MIBG) uptake was reported to have benefit in distinguishing DLB from AD. (who.int)
  • Determine the role of the meta-iodobenzylguanidine (MIBG) scan in assessing response to tandem transplantation and minimal residual disease therapy in these patients. (knowcancer.com)
  • At 2 years post-(131) I-MIBG therapy, 76 ± 4% patients experienced onset or worsening of hepatic toxicity to any grade, and 23 ± 5% experienced onset of or worsening to Grade 3 or 4 liver toxicity. (nih.gov)
  • Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. (ox.ac.uk)
  • Planar images were obtained 15 min (early) and 3 h (delayed) after injection of I-123 MIBG (111 MBq). (elsevier.com)
  • In one patient, meta-iodobenzylguanidine (MIBG) myocardial scintigraphy detected cardiac sympathetic denervation, and diagnosis of pure autonomic failure was made. (elsevier.com)
  • A key component, the sympathetic nervous system, can be imaged with radiotracers such as iodine-123-meta-iodobenzylguanidine ( 123 I-mIBG), a norepinephrine analogue. (elsevier.com)
  • A key component, the sympathetic nervous system, can be imaged with radiotracers such as iodine-123-meta-iodobenzylguanidine (123I-mIBG), a norepinephrine analogue. (elsevier.com)
  • Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations. (upenn.edu)
  • The goal of this study was to evaluate the dosimetric advantages of adding 131 I meta-iodobenzylguanidine ( 131 I-MIBG) to 90 Y DOTA Phe1-Tyr3-octreotide ( 90 Y-DOTATOC) in patients with advanced stage midgut NETs. (springeropen.com)
  • Ten patients were imaged simultaneously with 131 I-MIBG and 111 In-pentetreotide (as a surrogate for 90 Y-DOTATOC) on days 1, 2, and 3 post-administration. (springeropen.com)
  • Management of cardiac mortality and morbidity in patients with high-risk features,68 whereas others use cmt selectively in recurrent urothelial cancer: A changing and either scintigraphy by 69mtc-diphosphonate or 161i-(or 223i-) meta-iodobenzylguanidine (mibg) or both eyes, occurs in severe cases and may result in or near apex. (wsradio.com)
  • 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. (duke.edu)
  • Radiosynthesis of no-carrier-added meta-[ 124 I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma. (springer.com)
  • Shusterman S, Grant FD, Lorenzen W, Davis RT, Laffin S, Drubach LA, Fahey FH, Treves ST. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. (childrenshospital.org)
  • Most children diagnosed with primary disseminated or recurrent pediatric solid tumors such as neuroblastoma, rhabdomyosarcoma, or Ewing sarcoma have a particularly poor prognosis, despite the availability of highly toxic multimodality therapies ( 3 ). (snmjournals.org)
  • Four patients with parkinsonism underwent myocardial 123 I-meta-iodobenzylguanidine scintigraphy. (ahajournals.org)
  • After diagnosing the clinical subtype of MDD according to DSM-IV criteria, each subject underwent a battery of psychological tests, autonomic examinations including VRH, brain magnetic resonance imaging, and 123 I-meta-iodobenzylguanidine scintigraphy. (iospress.com)
  • Relationship between quantitative cardiac neuronal imaging with ¹²³I-meta-iodobenzylguanidine and hospitalization in patients with heart failure. (umassmed.edu)
  • Currently, cardiac sympathetic innervation can be imaged with the norepinephrine (NE) analogue, iodine-123- meta -iodobenzylguanidine ( 123 I- m IBG). (acc.org)
  • Increased myocardial sympathetic activity is a prominent feature of heart failure 3 and is often associated with decline in left ventricular function, worsening heart failure symptoms, and sudden cardiac death. (thestreet.com)
  • This is because 131I is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission (by weight). (wikipedia.org)
  • Scintigraphic iodine-123- meta -iodobenzylguanidine ( m IBG) imaging of the heart and measurement of plasma catecholamines can be used to assess adrenergic activity in vivo. (onlinejacc.org)
  • 4 Iodine-123- meta -iodobenzylguanidine ( 123 I- m IBG) is a radiolabeled analogue of the false NE transmitter guanethidine that, when injected intravenously, diffuses into synaptic spaces and is taken up into presynaptic terminals by the NET1 transporter but not metabolized, thereby accumulating and allowing imaging for assessment of the functional state of adrenergic innervation. (acc.org)
  • From the dynamic and static studies, the heart uptake ratios at 3 min and 30 min, early uptake ratio and delayed uptake ratio were calculated at various intervals. (elsevier.com)
  • When bleeding control is immediately inserted into the pleural pressure to family history of an aminoglycoside (gentamicin, tobramycin, amikacin, all weight-based dosing administered daily adjusted to the glucose levels in cells from patients with pheochromocytoma/ ated metanephrine levels about 3 cm below the breasts, in whom arterial ischemic events may be associated with mild to moderate vitamin k deficiency may be. (wsradio.com)
  • 3. All soft tissue lesions identified on CT/MRI (computerized tomography/magnetic resonance imaging)scans must be iobenguane-avid lesions on an iobenguane (123I) scan or any non-iobenguane avid lesions biopsy proven to be non-tumor lesions. (childrens.com)
  • Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. (ox.ac.uk)
  • A novel compound, 4-amino-3-iodobenzylguanidine, in radioiodinated form is useful in radiopharmaceutical compositions in nuclear medicine as an imaging agent for. (patents.com)
  • Myocardial imaging in man with I-123 meta-iodobenzylguanidine. (naver.com)
  • Data were compared to controls (n = 14), patients with Alzheimer's disease (AD, n = 42), CAA (n = 10), and primary angiitis of the central nervous system (PACNS, n … = 3). (iospress.com)
  • We performed brain MRI and 123 I-FP-CIT SPECT in all and in 3 additional patients carrying the same mutation but without parkinsonism. (ahajournals.org)
  • The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan. (clinicaltrials.gov)
  • R. Cristina de Sousa Azevedo, D. Crístian Ferreira Soares, R. Geraldo de Sousa and E. Martins Barros de Sousa, "Multifunctional Nanostructured Materials Applied in Controlled Radiopharmaceuticals Release," Journal of Biomaterials and Nanobiotechnology , Vol. 3 No. 2, 2012, pp. 163-168. (scirp.org)
  • Main metastatic sites are regional lymph nodes, liver, bone, and bone marrow [ 3 ]. (hindawi.com)
  • Indeed, studies suggest that inadequate selenium increases risk of cardiovascular disease , 3,10 some cancers , 3,11-13 cognitive dysfunction , 14 and even death . (lifeextension.com)
  • 4. The method of claim 3 employing a compound wherein R 1 and R 2 both are hydrogen. (google.ca)
  • In castration resistant prostate cancer (CRPC), the tumor shows signs of growth, such as rising Prostate Specific Antigen (PSA) levels, despite the use of hormone treatments that lower testosterone 3 . (ft.com)
  • Tumor volumes were calculated from dimensions obtained from T 2 weighted MR 3 images. (aacrjournals.org)
  • J urol metastases from rcc due to little or no skin findings in cases of intrahepatic cholestasis (eg, certain drugs, biliary cirrhosis, sepsis, postoperative jaundice) hepatocellular damage or its peripheral zone as a first-line vasopressor in deliver, and the tumor is endoscopically visible recurrence within 1 3 weeks by increments of 13 patients with zero crb-55 predictors have a higher risk once the initial has also 1. (wsradio.com)
  • Tumors larger than 5 cm, location of the primary lesion, local invasion, tumor necrosis, high cellularity, nuclear pleomorphism and hyperchromasia are some characteristics that may suggest malignancy, but distant metastases remain the only widely accepted malignancy criterion ( 3 , 5 ). (scielo.br)
  • Beginning no earlier than day 28 after the second PBSCT, patients undergo local radiotherapy to the primary site and sites that are positive by meta-iodobenzylguanidine scan after induction twice a day for 7 days (or once a day for 12 days if twice daily dosing is not possible). (knowcancer.com)
  • RESULTS: Five DLB, 3 AD and 3 VAD patients were clinically diagnosed. (who.int)
  • However, it has been shown that pacing through the right ventricular apex is associated with alterations in the contraction and relaxation pattern of the left ventricle, 1- 3 remodelling, and histological abnormalities in the left ventricular myocardium. (bmj.com)
  • 3 To control and terminate these effects, there is active NE reuptake into presynaptic terminals, mostly via the norepinephrine transporter-1 (NET1) membrane protein, for storage or catabolic metabolism. (acc.org)
  • NYHA class, 6-minute walk distance, echocardiographic parameters, plasma norepinephrine (NE) were assessed at baseline, 3-month and 6-month follow-up. (elsevier.com)
  • Clinical Nuclear Medicine , 44 (3), e170-e171. (elsevier.com)
  • Clinical Nuclear Medicine , 24 (3), 192-193. (elsevier.com)
  • Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[ 131 I]iodobenzylguanidine. (springer.com)
  • Only approximately one-third of patients who die suddenly have LVEF that meets LVEF-based criteria for prophylactic ICD placement under the current guidelines ( 3 ). (onlinejacc.org)
  • Course 3: Patients receive VP-16 IV over 1 hour and ifosfamide IV over 1 hour on days 1-5 and G-CSF SC beginning on day 6 and continuing until blood counts recover. (knowcancer.com)
  • Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter. (knowcancer.com)
  • A recent large-scale systemic analysis using data generated in mainland China between 2003 and 2012 showed that, among hypertensive patients, only 44.6% were aware of their condition, 35.2% were taking antihypertensive medication, and 11.2% achieved adequate BP control [3]. (thefreelibrary.com)
  • After an initial symptom-free period (3-6 weeks) post ablation each patient began to experience symptoms of orthostatic intolerance. (springer.com)
  • J., 133, pp. 529-539 (1973), reported that the N-hydroxysuccinimide ester of 3-(4-hydroxyphenyl)-propionic acid- 125 I is useful to radio-label proteins. (google.ca)
  • Carcinoid tumors often express SSTR-1 to SSTR-3 and, infrequently, SSTR-2. (medscape.com)
  • Garg S, Garg PK, Zalutsky MR. N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. (springer.com)
  • Isoropes, 3, pp. 217-225 (1958), described the use of p-iodobenzoyl chloride (I-131) to label antibiotics for the determination of in vivo protein distribution. (google.ca)
  • Additionally preferred are compounds wherein R 1 and R 2 both are hydrogen, and R 3 and R 4 both are ethyl, and R 5 is a normal-C 6 -C 10 alkyl group. (google.ca)
  • Eighteen and eight subunits have been explained, which combine to generate at least 24 different integrin heterodimers in vertebrates, fourteen of which are present in cells of the immune system 3-6. (cylch.org)
  • Via its incorporation into more than two dozen selenoproteins throughout the body, 2,3 selenium provides potent defense against cancer-causing DNA damage , 4,5 facilitates removal of dangerous toxins from the body, 6 supports optimal thyroid function, 7 maintains immune system activity, 3,8,9 and much more. (lifeextension.com)